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ABSTRACT The 4-aminoquinoline chloroquine (CQ) is clinically used in combination
with doxycycline to cure chronic Q fever, as it enhances the activity of the anti-
biotic against the causative bacterium Coxiella burnetii residing within macrophage
phagolysosomes. As there is a similar cellular host-pathogen biology for Leishmania
parasites, this study aimed to determine whether such an approach could also be
the basis for a new, improved treatment for cutaneous leishmaniasis (CL). We have
evaluated the in vitro and in vivo activities of combinations of CQ with the standard
drugs paromomycin (PM), miltefosine, and amphotericin B against Leishmania major
and Leishmania mexicana. In 72-h intracellular antileishmanial assays, outcomes were
variable for different drugs. Signiﬁcantly, the addition of 10 M CQ to PM reduced
50% effective concentrations (EC50s) by over 5-fold against L. major and against nor-
mally insensitive L. mexicana parasites. In murine models of L. major and L. mexicana
CL, daily coadministration of 50 mg/kg of body weight PM and 25 mg/kg CQ for 10
days resulted in a signiﬁcant reduction in lesion size but not in parasite load com-
pared to those for mice given the same doses of PM alone. Overall, our data indi-
cate that PM-CQ combination therapy is unlikely to be a potential candidate for fur-
ther preclinical development.
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Cutaneous leishmaniasis (CL) is a group of skin infections caused by obligateintracellular protozoa belonging to the genus Leishmania, which are transmitted
via the bite of female sandﬂies. Over 15 different parasite species are responsible for CL
in humans, with a diverse clinical spectrum ranging from self-limiting but scarring skin
lesions (localized CL) to rarer and more complex forms of CL. These forms can be diffuse
(diffuse cutaneous leishmaniasis), chronic (leishmaniasis recidivans), and destructive to
the mucosal tissue (mucocutaneous leishmaniasis) (1). The estimated global prevalence
is 12 million cases per year in more than 98 countries (the majority of which occurs in
Latin America and the Middle East), and more than 350 million people are at risk (2).
Despite its increasing incidence (3) and high burden (due to physical disﬁgurement and
related social stigmatization), vaccines and satisfactory treatment options are currently
lacking for this poverty-related and neglected tropical disease. A painful and lengthy
series of injections of toxic pentavalent antimonials, associated with severe side effects
and reduced sensitivity in some species, still remains the ﬁrst-line therapy after more
than 7 decades of clinical use (4). More recent second-line drugs, such the aminogly-
coside antibiotic paromomycin (PM), the phospholipid miltefosine (MF), and the poly-
ene antifungal amphotericin B (AmB) (available in deoxycholate salts or lipid nanopar-
ticle formulations), also suffer from similar limitations related to toxicity, efﬁcacy, cost,
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or an invasive administration route. There is an urgent requirement for new treatments
that can eliminate the parasite and safely accelerate lesion healing with minimal
scarring and are feasible for use in low-resource health care systems (5, 6). In recent
years, combination therapy of commercially available drugs has received more atten-
tion as an alternative strategy to develop more effective, lower-dose, and shorter
treatments for many infectious diseases, including CL (7–11). With the goal of identi-
fying such an improved therapeutic option for Leishmania major and Leishmania
mexicana CL, we investigated the potential of the cheap, safe, and orally bioavailable
4-aminoquinoline chloroquine (CQ) to increase the activities of three standard antil-
eishmanial drugs. The rationale for this approach was based upon evidence that the
addition of CQ to treatment regimens for chronic stages of Q fever shortens the
duration of therapy and prevents relapses (12, 13). CQ enhances the antimicrobial
activity of doxycycline against the causative obligate intracellular bacterium Coxiella
burnetii, which resides and multiplies within the phagolysosomes of its macrophage
host cells (14). Likewise, CQ improves the effects of speciﬁc antibiotics against other
intracellular pathogens such as Tropheryma whipplei (Whipple’s disease) and persistent
Staphylococcus aureus populations in chronic systemic infections (15, 16). Despite the
similar macrophage tropism of Leishmania species causing CL, the effect of CQ on the
activity of standard antileishmanial drugs has not yet been evaluated. Thus, in this
study, our aim was to determine whether combination therapies of PM, MF, and AmB
deoxycholate with CQ could be a new approach for the treatment for CL. Promising
associations identiﬁed during in vitro screenings were then assessed in vivo by using
murine models of L. major and L. mexicana CL. These Old and New World species were
compared due to their known differences in drug sensitivities (17) and morphological
characteristics of the parasitophorous vacuoles (18).
RESULTS AND DISCUSSION
We investigated the possible enhancing effect of CQ on the in vitro activities of three
standard antileishmanial drugs against intracellular L. major and L. mexicana. A speciﬁc
CQ concentration of 10 M was selected because of (i) the lack of host cell cytotoxicity
(the viabilities of peritoneal exudate macrophages [PEMs] were determined to be
85.8% 15.6% and 100% 0% in alamarBlue and lactate dehydrogenase [LDH] assays,
respectively), (ii) the absence of independent antileishmanial effects (the percent
inhibition against L. major and L. mexicana amastigotes was 5% compared to un-
treated controls), and (iii) the reported enhanced activity of different antibiotics against
other intramacrophage pathogens at similar CQ concentrations (14–16). We observed
various effects of coincubation with 10 M CQ for different drugs in standard 72-h drug
assays (Table 1). A small but signiﬁcant (P  0.0001) increase in antileishmanial activity
was found for MF against L. major (50% effective concentrations [EC50s] decreased from
33.9 5.9 to 10.7 1.8 M) but not for L. mexicana (from 15.7 1.0 to 10.0 1.6 M).
In the case of AmB, combination with CQ was highly toxic to host cells, and EC50s were
incalculable. For PM, coincubation with CQ resulted in a signiﬁcant (P  0.0001) 5-fold
decrease in EC50s against L. major (from 58.1 6.1 to 11.6 2.4 M) and reduced EC50s
against L. mexicana, from 360 M (i.e., too high to accurately estimate because the
TABLE 1 In vitro activities of miltefosine, amphotericin B, and paromomycin in monotherapy (alone) and in combination therapy with 10
M CQ (plus CQ) against intracellular L. major and L. mexicana in PEMs after 72 ha
Organism
EC50 (M) % infection PEMs (72 h)
Miltefosine
Amphotericin B alone
Paromomycin
Untreated
Treated with
10 M CQAlone Plus CQ Alone Plus CQ
L. major 33.9 5.9 10.7 1.8* 9.9  102 0.6  102 58.1 6.1 11.6 2.4* 98 97.5
L. mexicana 15.7 1.0 10.0 1.6 9.9  102 0.5  102 360 86.6 17.4 98.5 96.8
aData are expressed as means  95% CI. *, statistically signiﬁcant difference in EC50s for drugs as monotherapy and CQ combination therapy (P  0.05 by an extra-
sum-of-squares F test). With amphotericin B plus CQ, there was microscopically visible cytotoxicity toward PEMs. After 72 hours, viability of PEMs treated with 10 M
CQ alone was 85.8%  15.6% (alamarBlue assay) and 100%  0% (LDH assay).
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concentration was above the maximum drug level tested) to 86.6  17.4 M (no P
value was calculable). The improved activity of PM by the addition of CQ was notable
because of the known relative insensitivity of L. mexicana to this aminoglycoside
antibiotic (19–21). Thus, of the three standard antileishmanial drugs tested, PM in
combination with CQ was evaluated further.
Next, the concentration dependency of the enhancing effect of CQ on the anti-
leishmanial activity of PM was determined. Fixed concentrations of PM with multiple
CQ doses (all 10 M, due to macrophage cytotoxicity at higher concentrations, with
the 50% lethal concentration [LC50] being 18.1  2.9 M) were tested against promas-
tigotes and amastigotes of L. major and L. mexicana. Figure 1 shows the corresponding
dose-response curves. Increasing CQ concentrations from 0 to 5 to 10 M did not alter
the antileishmanial activity of PM against extracellular promastigotes, with respective
EC50s of 33.3  8.4, 32.2  8.3, and 27.3  12.3 M for L. major and 360 M for all
three concentrations for L. mexicana. In contrast, we observed a gradual decrease in
EC50s against intracellular amastigotes as CQ levels similarly increased (from 91.7 11.2
to 31.0  4.0 to 16.9  1.6 M against L. major and from 360 M to 182.1  25.7 to
86.7  22.3 M against L. mexicana). The mechanism of in vitro synergy between CQ
and PM to eliminate the intracellular parasites within the parasitophorous vacuoles of
the PEMs remains unclear. For the Q fever agent C. burnetii, the mode of action for CQ
to enhance the antimicrobial activity of doxycycline, a pH-sensitive antibiotic, is related
to its ability to accumulate within the normally acidic macrophage phagolysosomes
and alkalinize this pathogen-harboring organelle (14). A similar host-pathogen inter-
action could be taking place in this setting, as indicated by (i) the presence of
lysosomotropic properties of CQ at 10 M (14–16), (ii) the absence of host cell toxicity
and antileishmanial activity of CQ at the chosen concentration, (iii) the speciﬁcity of the
association synergy for intracellular over extracellular parasites, (iv) the acidophilic
nature of Leishmania (22), and (v) the reduced activity of aminoglycoside antibiotics
such as PM at acidic pH (23). However, this hypothesis was not conﬁrmed as we did not
FIG 1 Effect of CQ on the in vitro antileishmanial activity of PM against intracellular and extracellular L. major (left) and L. mexicana (right) parasites. For the
amastigote drug assays (top row), PEMs were infected with stationary-phase promastigotes and exposed to ﬁxed PM concentrations (13.3, 40, 120, and 360 M)
combined with 0 to 5 to 10 M CQ for 72 h, followed by microscopic counting of the number of infected macrophages. For the promastigote drug assays
(bottom row), exponential-growth-phase parasites were treated identically, and inhibition was evaluated by using the alamarBlue assay. Values are expressed
relative to untreated controls (percent inhibition). 10 M CQ  indicates the percent inhibition at 10 M CQ.
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test whether increased phagolysosomal pH is linked to improved antileishmanial
activity.
Finally, the efﬁcacy of the PM-CQ combination was assessed in murine models of CL
caused by the selected Leishmania species. For L. major- and L. mexicana-infected
rodents, differences in lesion sizes and day 10 parasite loads among the groups were
analyzed (Fig. 2). There was a good correlation between lesion size (Fig. 2a) and parasite
load (Fig. 2b) in the L. major BALB/c model. Compared to the untreated controls
(phosphate-buffered saline [PBS]), lesion sizes in L. major-infected animals receiving
only 25 mg/kg of body weight CQ were slightly smaller (but the difference between the
groups was insigniﬁcant; P  0.072) but were signiﬁcantly reduced in the groups
receiving 50 mg/kg PM and 50 mg/kg PM plus 25 mg/kg CQ (PM-CQ) (P  0.0001 for
both). When mice treated with PM alone were compared to those treated with PM-CQ,
lesions in the combination group were smaller and fully resolved (0  0 mm) 1 day
earlier (by day 8 versus day 9), but the difference was not statistically signiﬁcant (P 
0.823). The parasite load was not signiﬁcantly reduced in the CQ group compared to
the untreated group (P  0.062) but was signiﬁcantly lower for PM alone and the
PM-CQ groups (P  0.006 for both). No additional reduction in parasite load was found
between the PM and PM-CQ groups (1.0  106  0.8  106 amastigotes per g skin
tissue for both), and the difference was insigniﬁcant (P  0.999). For the in vivo
experiment with L. mexicana, lesion sizes (Fig. 2c) again correlated fairly well with
parasite loads (Fig. 2d). L. mexicana lesion sizes in rodents treated with PM, CQ, and
PM-CQ were not signiﬁcantly reduced compared to those in the placebo group (P 
FIG 2 Evaluation of the in vivo efﬁcacy of the combination of PM and CQ in murine models of L. major (left) and L. mexicana (right) CL. Female BALB/c mice
were infected with stationary-phase promastigotes in the rump above the tail (n  3 to 5 per group). At 12 days (L. major) and 6 weeks (L. mexicana)
postinoculation, animals presenting with CL nodules were dosed daily via the i.p. route for 10 consecutive days with PBS (control), 50 mg/kg PM, 25 mg/kg
CQ, or a combination of 50 mg/kg PM and 25 mg/kg CQ (PMCQ). One day after the administration of the last dose (day 10), animals were sacriﬁced, lesions
were harvested, and parasite burden was quantiﬁed by DNA-based qPCR. Lesion size evolution (a and c) and lesion parasite load at the end of treatment (b
and d) are shown as means and SD. ANOVA (1 way for parasite load and repeated measures for lesion size) followed by Turkey’s multiple-comparison tests was
used to compare outcomes among the groups. The difference between untreated controls and individual PM-, CQ-, and PM-CQ-treated groups was considered
statistically signiﬁcant if the P value was 0.05 (**, P  0.001) or insigniﬁcant if not (ns).
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0.999, P  0.890, and P  0.216, respectively). However, in speciﬁc comparisons of the
PM and PM-CQ groups at the end of treatment (day 10), the lesion sizes were smaller
for the combination group (3.1  0.8 versus 6.0  1.4 mm), and the difference at this
time point was signiﬁcant (P  0.0014). Parasite burdens were similar in the placebo,
PM, CQ, and PM-CQ groups (P  0.05 for all differences). No signiﬁcant difference (P 
0.824) between parasite loads in the PM-CQ group (7.0  106  9.3  106) and the
PM-alone group (3.4  106  2.2  106) was found. Over the course of treatment of
L. major- and L. mexicana-infected mice, no events of severe weight loss or adverse
drug effects occurred (data not shown).
We conclude that while combination therapy of 50 mg/kg PM combined with 25
mg/kg CQ did not show increased toxicity, there was not signiﬁcant additional activity
compared to those of the component drugs. Against both tested Leishmania species,
the association resulted in a small decrease in lesion size toward the end of treatment
(which is remarkable for L. mexicana CL due to the known and hereby conﬁrmed
unresponsiveness of this species to PM treatment), but the corresponding parasite
loads were not signiﬁcantly reduced. The independent anti-inﬂammatory properties of
CQ rather than a synergistic mechanism with PM might explain this phenomenon, as
we also observed a small but not signiﬁcant suppressive effect on lesion size in controls
treated with CQ alone. While the inhibition of proinﬂammatory cytokine production
and release could hinder classic macrophage activation and the consequent elimina-
tion of intracellular parasites, this may reduce skin tissue damage and prevent further
inﬂammation-driven lesion proliferation (24–26). Furthermore, antileishmanial activity
of CQ in the L. amazonensis CBA mouse ear model has been reported, although this was
observed after higher-dose oral treatment (50 mg/kg) over longer periods (5 weeks)
(27).
The poor in vitro-in vivo translation of the PM-CQ combination might be explained
by several factors. First, skin pharmacokinetics could play a role. The daily 50-mg/kg PM
regimen over a 10-day period showed efﬁcacy, in agreement with data from previous
work with the L. major-BALB/c mouse model (28), indicating that the drug must be
bioavailable at the dermal infection site to exert its antileishmanial activity. Based on
the extrapolation of data on CQ accumulation in rat skin after intraperitoneal (i.p.)
administration (29, 30), the daily 25-mg/kg dose regimen over 10 days should have
resulted in the desired dermal micromolar concentrations within the chosen time
frame. The ability of CQ to sequestrate in skin has been extensively reported, as it is
used in the treatment of cutaneous lupus and is thought to be a factor in adverse
reactions such as pruritus and itching (31). Moreover, Leimer and colleagues (16)
showed the additional efﬁcacy of ﬂucloxacillin-CQ compared to the antibiotic as
monotherapy against S. aureus in a murine systemic infection model after only 2 i.p.
doses of 10 mg/kg CQ over a period of 3 days. Hence, while exposure levels of CQ and
PM at the target site were likely sufﬁcient to allow theoretical synergy between the
drugs, this could not be conﬁrmed experimentally. Second, in the dermis, CQ might not
be able to penetrate infected macrophages to interact with PM for the elimination of
intracellular parasites. Ionization of CQ in the acidiﬁed extracellular ﬂuid present in
many tumors is known to limit its passive passage through the membranes of the
targeted cancer cells (32). The well-known phenomenon of local acidosis in inﬂamed
tissues (33), such as Leishmania-infected skin (34), could have led to a similar limitation
of uptake at this site. Third, there may be in vivo antagonistic effects between PM and
CQ. This is unlikely because the drugs have not been reported to affect each other’s
absorption, distribution, metabolism, or excretion (30). Finally, although the in vitro
intracellular amastigote drug assay using murine macrophages has proven to be a
suitable model to predict in vivo activity in mice, the lack of biological relevance
(macrophage behavior and the presence of many other types of cells and compounds
under physiological conditions) might confound this assumption. There is still a need
for more complex in vitro antileishmanial drug assays to bridge this gap in preclinical
CL drug research. Taken together, the variable susceptibilities of L. major and L.
mexicana to the tested drugs also highlight the vast challenge in the identiﬁcation of
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a single new (combination) treatment active against the plethora of Leishmania species
causing CL.
In summary, our data suggest that the high-dose combination of PM and CQ
provides only limited enhanced efﬁcacy (mild effect on the evolution of lesion sizes
without an additional reduction in parasite burdens) in L. major- and L. mexicana-
infected mice compared to PM monotherapy. These ﬁndings indicate that further
research, such as optimization of the drug dose ratio, into this combination as a novel
treatment for CL is not justiﬁed.
MATERIALS AND METHODS
Drugs. For the in vitro drug assays, stocks of paromomycin sulfate (20 mM [aq]; Sigma, UK), MF (20
mM [aq]; Paladin Inc., UK), amphotericin B deoxycholate (5.2 mM [aq]) (Fungizone; Gibco, UK), and
chloroquine diphosphate (10 mM [aq]; Sigma, UK) were prepared, aliquoted, and kept at20°C until use.
From the same original drug batches, solutions in PBS (0.9% NaOH [pH 7.4]; Sigma, UK) were made for
the rodent experiments (mean weight per animal of 20 g) at concentrations of 50 mg/kg PM (5.797
mg/ml), 25 mg/kg CQ (4.032 mg/ml), and 50 mg/kg PM plus 25 mg/g kg CQ (coadministration of the
same doses).
Macrophages. Peritoneal mouse macrophages (PEMs) were obtained from female 8- to 12-week-old
CD1 mice. A 2% (wt/vol) starch (VWR, USA) solution in PBS was injected i.p., and PEMs were harvested
24 h later by peritoneal lavage with RPMI medium containing 1% penicillin-streptomycin (PenStrep;
Sigma, UK). After centrifugation at 1,500 rpm at 4°C for 15 min, the supernatant was removed, and the
pellet was resuspended in minimal essential medium Eagle (MEME; Sigma, UK) with 10% heat-inactivated
fetal calf serum (HiFCS; Gibco, UK). The number of cells was estimated by counting with a Neubauer
hemocytometer using light microscopy (40 magniﬁcation).
Parasites. L. majorMHOM/SA85/JISH118 and L. mexicanaMNYC/BZ/62/M379 parasites were cultured
in Schneider’s insect medium (Sigma, UK) supplemented with 10% HiFCS. These parasites were passaged
each week at a 1:10 ratio of the existing culture to fresh medium in 25-ml culture ﬂasks without a ﬁlter
and incubated at 26°C. For infection of macrophages (in vitro) and mice (in vivo), stationary-phase
parasites (as conﬁrmed by light microscopy) were centrifuged for 10 min at 2,100 rpm at 4°C. The
supernatant was removed, and the pellet was resuspended in MEME containing 10% HiFCS. The number
of cells was estimated by microscopic counting with a Neubauer hemocytometer.
Cytotoxicity assays. Macrophages in a 200-l suspension (4  105 macrophages per ml) were
allowed to adhere to the bottom of 96-well plates for 48 h and then exposed to speciﬁc drug
concentrations over 72 h. Cytotoxicity was evaluated by using the alamarBlue assay (Serotec, UK) and a
lactate dehydrogenase assay (LDH kit; Promega, UK) to assess metabolism (cell viability) and enzyme
leakage through damaged cell membranes (cell death), respectively. After the addition of alamarBlue
(10%) to 150 l of the treated PEM culture, the latter was incubated at 37°C in 5% CO2, and viability was
measured over a period of 1 to 24 h by ﬂuorescence (SpectraMax M3 plate reader; Molecular Devices)
at a wavelength of 530 nm, with a 580-nm emission wavelength and a 550-nm cutoff. Results were
expressed as percent viability compared to the untreated controls after correction for the blank signal.
In separate wells, an LDH substrate mix was added to 50 l of the treated PEM culture at a 1:1 ratio. The
plates were incubated at room temperature for 30 min on a mechanical shaker with slow rotation. Stop
solution (50 l) was then added, and the absorbance at 490 nm was determined. Results were expressed
as percent cell death compared to the positive controls (PEMs treated with 80 M podophyllotoxin;
Sigma, UK) after correction for the blank. An alamarBlue assay (with the same experimental settings as
the ones described above for macrophages) was also used to assess the viability of exponential-phase
promastigotes during drug assays. Results were expressed as percent inhibition  100%  x% viability
(means  95% conﬁdence intervals [CI]).
Seventy-two-hour intracellular antileishmanial drug activity assay. One hundred microliters of
the PEM culture (4  105 macrophages per ml) was added to each well of 16-well LabTek culture slides
(Thermo Fisher, UK) and incubated for 24 h at 37°C in 5% CO2. Host cells were then infected at a 1:3 ratio
(L. major or L. mexicana) using 100 l stationary-phase low-passage-number parasites and further
incubated for 24 h at 34°C in 5% CO2. On the day of treatment, drug stocks were thawed and diluted to
the appropriate concentrations. After conﬁrmation that macrophage infection levels were above 80%
(light microscopy), extracellular parasites were removed by washing, and 100 l of a drug dilution in
MEME with 10% HiFCS, alone or supplemented with 10 M CQ, was added to the infected PEMs. The ﬁnal
drug concentrations were 360 M for PM, 30 M for MF, and 0.5 M for AmB, which were 1:3 serially
diluted, resulting in quadruplicates of 4 different concentrations. After incubation for 72 h at 34°C, the
medium was removed, and the slides were ﬁxed with 100% methanol for 2 min and stained with 10%
Giemsa for 10 min. The number of infected cells was then measured under each treatment condition by
microscopically counting 100 macrophages. The percentage of infected cells after treatment was
determined and expressed relative to the untreated control (percent inhibition). Dose-response curves
and EC50s were calculated by using GraphPad Prism version 7.02 software. Results represent means 
95% CI.
In vivo L. major and L. mexicana models of CL. Female BALB/c mice around 6 to 8 weeks old were
purchased from Charles River Ltd. (Margate, UK). These mice were kept in humidity- and temperature-
controlled rooms (55 to 65% and 25 to 26°C, respectively) and fed water and rodent food ad libitum. After
acclimatization for 1 week, mice were randomized and subcutaneously (s.c.) infected in the shaven rump
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above the tail with 200 l of a parasite suspension containing 4  107 low-passage-number (P  5),
stationary-phase L. major or L. mexicana promastigotes in RPMI medium. Lesion size was measured daily,
and treatment was not started until the development of a 3- to 4-mm nodule. Animals were allocated
to 4 groups (n 3 for L. mexicana and n 5 for L. major in vivo assays) to ensure comparable lesion sizes
under each condition. Mice were treated every 24 h with 25 mg/kg CQ, 50 mg/kg PM, or a combination
of these drugs at the same doses for 10 days (in PBS, by the i.p. route). The control group received a
similar volume (200 l) of PBS (i.p.). Drug efﬁcacy was evaluated by daily measurements of lesion size and
quantiﬁcation of parasite loads in the infected skin at the end of treatment. Digital calipers were used to
determine the mean size of the nodule in 2 dimensions (length and width). Body weight was recorded
daily to monitor clinical deterioration due to pathology or systemic drug toxicity.
Ethics statement. All animal experiments were conducted under license X20014A54 according to UK
Home Ofﬁce regulations under the Animals (Scientiﬁc Procedures) Act 1986 and EC Directive 2010/63/E.
Parasite DNA extraction from lesions and parasite loads. The harvested lesion was cut into 1- to
2-mm-long pieces and placed into SureLock microcentrifuge tubes (StarLab, UK) together with 1 ml PBS
and 100 mg of 2-mm zirconium oxide beads (NextAdvance, UK). The tissue was ground by using a
BulletBlender Storm 24 instrument (NextAdvance, UK) set at maximum speed (setting 12) for 15 min.
DNA from a 200-l volume of the homogenate was extracted by using the Qiagen DNeasy kit for blood
and tissue. Twenty microliters of proteinase K and 200 l tissue lysis buffer were added, mixed, and left to
incubate for 1 h in a water bath at 56°C. According to the manufacturer’s protocols, DNA was precipitated
by using ethanol and transferred to a DNeasy minicolumn, which retained DNA during multiple washing
steps until 50 l was eluted with the appropriate buffer. For the calibration curve standards, this DNA
extract from 109 L. major or L. mexicana promastigotes was added to 450 l water, and consequent serial
dilutions ranging from 108 to 101 were made. A previously established quantitative PCR (qPCR) meth-
odology based on the ampliﬁcation of the 170-bp region in the Leishmania 18S gene (35) was used to
quantify the parasite burden in the lesion. Two-microliter DNA extract samples (diluted 1/100) were
ampliﬁed in 10-l reaction mixtures in the presence of 5 l SensiFAST SYBR No-ROX master mix, 0.25 M
probe, and 0.4 M each primer. Each run included a negative or no-template control where master mix
or DNA was replaced by puriﬁed water, respectively. Triplicates of standards (108 to 101) and duplicates
of unknown samples were included. The tubes were placed into a 72-sample rotor of the RotorGene 3000
instrument, set at 40 cycles at a denaturation setting of 95°C for 5 min followed by a 2-step ampliﬁcation
cycle of 95°C for 10 s and 60°C for 30 s.
Statistical analysis. For the outcomes of in vitro assays (Fig. 1), the percentage of inhibition was
expressed relative to the untreated 72-h control, and the corresponding sigmoidal dose-response curves
were established by using a nonlinear ﬁt with variable slope models. Related EC50s were compared by
using extra-sum-of-squares F tests. For in vivo experiments (Fig. 2), the differences in lesion sizes and
parasite loads among the groups were assessed by using repeated-measures 2-way analysis of variance
(ANOVA) and 1-way ANOVA, both of which were followed by Tukey’s multiple-comparison test. In vitro
data are presented as means  95% CI, and in vivo data are presented as means  standard deviations
(SD). P values of 0.05 were considered statistically signiﬁcant. All analyses were performed by using
GraphPad Prism version 7.02.
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